Comparison · NCT00856492-a056685c
Arm 1 (Nab-Paclitaxel + Bevacizumab - AC+PEG-G)) vs Arm 2/3 (Nab-Paclitaxel/AC+PEG-G)): Number of Patients With Pathological Complete Response Rate
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Arm 1 (Nab-Paclitaxel + Bevacizumab - AC+PEG-G)) vs Arm 2/3 (Nab-Paclitaxel/AC+PEG-G)): Number of Patients With Pathological Complete Response Rate. Trial comparisons, record NCT00856492-a056685c. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00856492-a056685c
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.357 | 0.269 | 0.456 | wilson | |
| Risk in group 2 | 0.212 | 0.147 | 0.297 | wilson | |
| Risk difference, group 1 minus group 2 | 0.145 | 0.0231 | 0.263 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.68 | 1.08 | 2.62 | log | |
| Odds ratio, group 1 over group 2 | 2.06 | 1.12 | 3.8 | log | |
| Number needed to treat, for one more participant with the outcome on Arm 1 (Nab-Paclitaxel + Bevacizumab - AC+PEG-G)) than on Arm 2/3 (Nab-Paclitaxel/AC+PEG-G)) | 6.91 | 3.8 | 43.3 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Arm 1 (Nab-Paclitaxel + Bevacizumab - AC+PEG-G)) | Received intravenous (IV) administration of nabpaclitaxel 100 mg/m2 IV weekly for 12 weeks (nP x 12) with IV bevacizumab 10 mg/kg every 2 weeks (six doses), followed by IV doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 with pegfilgrastim 6 mg subcutaneously every 2 weeks for six cycles (ddAC x 6). | 35 | 98 | OG000 |
| Group 2 | Arm 2/3 (Nab-Paclitaxel/AC+PEG-G)) | Received nP x 12 followed by ddAC x 6, or received ddAC x 6 first followed by nP x 12, without bevacizumab | 24 | 113 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- Number of Patients With Pathological Complete Response Rate
- Description
Pathologic complete response (pCR), commonly defined as the absence of residual invasive cancer in both the breast and axillary lymph nodes, has emerged as a surrogate endpoint for disease-free and overall survival, as the achievement of a pCR is associated with a favorable long-term prognosis in all breast cancer subtypes.
- Time frame
- pre-study pathology vs. post-chemo surgery pathology (approx. 39-42 weeks post-randomization)
- Population
- Pre-specified analysis of Arm 1 vs. Arm 2/3 to compare effect of bevacizumab
Source ClinicalTrials.gov
Trial
- Title
- S0800, Nab-Paclitaxel, Doxorubicin, Cyclophosphamide, and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer
- NCT number
- NCT00856492
- Phases
- PHASE2
- Conditions
- Breast Cancer
- Interventions
- bevacizumab, pegfilgrastim, cyclophosphamide, doxorubicin hydrochloride, paclitaxel albumin-stabilized nanoparticle formulation
- Lead sponsor
- SWOG Cancer Research Network
- Results first posted
- 2017-06-27
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00856492?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00856492-a056685c